Physician profile
Katie A Sowder
NPI 1528306289
$2,602.62
in general payments reported to CMS, 2019-2025
27 companies · $660 in 2025
The $660 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $305 · 2023: $696 · 2024: $785 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.59 |
| Education | $176.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.86 | 2021-2025 | |
| Harmony Biosciences LLC | $286.12 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $228.29 | 2021-2025 | Airsupra, Farxiga, Fasenra |
| Exact Sciences Corporation | $214.35 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $203.32 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $160.52 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $137.96 | 2022-2024 | Rexulti |
| Amarin Pharma, INC. | $67.80 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.83 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $45.24 | 2023-2024 | |
| Eisai INC. | $43.69 | 2024-2025 | |
| Astellas Pharma US INC | $43.44 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $32.65 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.93 | 2023-2024 | |
| Inspire Medical Systems, INC. | $26.27 | 2025 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.67 | 2024 | Otezla, Repatha |
| Organon LLC | $23.12 | 2021 | |
| Lilly USA, LLC | $22.52 | 2025 | Zepbound |
| Philips North America LLC | $20.68 | 2023 | |
| Almatica Pharma LLC | $20.51 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.04 | 2024 | |
| Boston Scientific Corporation | $19.43 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.08 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $15.40 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.60 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $12.31 | 2022 | |
| Genentech USA, INC. | $9.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Sowder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.